ECSP088501A - FORMA CRISTALINA DE 1´-(1-METILETIL)-4´-[(2-FLUORO-4-METOXIFENIL)METIL]-5´-METIL-1H-PIRAZOL-3´-O-ß-D-GLUCOPIRANÓSIDO, UN MÉTODO PARA SU PREPARACIÓN Y EL USO DE LA MISMA PARA PREPARAR MEDICAMENTOS - Google Patents

FORMA CRISTALINA DE 1´-(1-METILETIL)-4´-[(2-FLUORO-4-METOXIFENIL)METIL]-5´-METIL-1H-PIRAZOL-3´-O-ß-D-GLUCOPIRANÓSIDO, UN MÉTODO PARA SU PREPARACIÓN Y EL USO DE LA MISMA PARA PREPARAR MEDICAMENTOS

Info

Publication number
ECSP088501A
ECSP088501A EC2008008501A ECSP088501A ECSP088501A EC SP088501 A ECSP088501 A EC SP088501A EC 2008008501 A EC2008008501 A EC 2008008501A EC SP088501 A ECSP088501 A EC SP088501A EC SP088501 A ECSP088501 A EC SP088501A
Authority
EC
Ecuador
Prior art keywords
methyl
same
fluoro
preparation
methytile
Prior art date
Application number
EC2008008501A
Other languages
English (en)
Inventor
Peter Eickelmann
Leo Thomas
Gerd F Kraemer
Adil Duran
Hans-Juergen Martin
Klaus Dugi
Sabine Pinnetti
Regine Ritter
Ruediger Streicher
Gebhard Adelgoss
Gebhard Schilcher
Steffen Maier
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of ECSP088501A publication Critical patent/ECSP088501A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se refiere a una forma cristalina de 1´-(1-metiletil)-4´-[(2-fluoro-4-metoxifenil)metil]-5´-metil-1H-pirazol-3´-O-b-D-glucopiranósido, a un método para la preparación de la misma, así como al uso de la misma para preparar medicamentos.
EC2008008501A 2006-01-11 2008-06-04 FORMA CRISTALINA DE 1´-(1-METILETIL)-4´-[(2-FLUORO-4-METOXIFENIL)METIL]-5´-METIL-1H-PIRAZOL-3´-O-ß-D-GLUCOPIRANÓSIDO, UN MÉTODO PARA SU PREPARACIÓN Y EL USO DE LA MISMA PARA PREPARAR MEDICAMENTOS ECSP088501A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06000483 2006-01-11

Publications (1)

Publication Number Publication Date
ECSP088501A true ECSP088501A (es) 2008-07-30

Family

ID=35953998

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008501A ECSP088501A (es) 2006-01-11 2008-06-04 FORMA CRISTALINA DE 1´-(1-METILETIL)-4´-[(2-FLUORO-4-METOXIFENIL)METIL]-5´-METIL-1H-PIRAZOL-3´-O-ß-D-GLUCOPIRANÓSIDO, UN MÉTODO PARA SU PREPARACIÓN Y EL USO DE LA MISMA PARA PREPARAR MEDICAMENTOS

Country Status (19)

Country Link
US (2) US7524822B2 (es)
EP (1) EP1976859A1 (es)
JP (1) JP4936234B2 (es)
KR (1) KR20090012205A (es)
CN (1) CN101370816A (es)
AR (1) AR058962A1 (es)
AU (1) AU2007204368A1 (es)
BR (1) BRPI0706375A2 (es)
CA (1) CA2635203A1 (es)
EA (1) EA200801663A1 (es)
EC (1) ECSP088501A (es)
IL (1) IL192655A0 (es)
NO (1) NO20082395L (es)
NZ (1) NZ570311A (es)
PE (1) PE20071237A1 (es)
TW (1) TW200745149A (es)
UY (1) UY30082A1 (es)
WO (1) WO2007080170A1 (es)
ZA (1) ZA200804151B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003272903A1 (en) * 2002-10-04 2004-04-23 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2548578T3 (es) * 2007-12-27 2015-10-19 Kissei Pharmaceutical Co., Ltd. Monosebacato de un derivado de pirazol
WO2009128421A1 (ja) * 2008-04-16 2009-10-22 キッセイ薬品工業株式会社 ピラゾール誘導体の１／２フマル酸塩
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20110118668A (ko) 2009-02-13 2011-10-31 베링거 인겔하임 인터내셔날 게엠베하 １형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ­２ 억제제
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101019079B1 (ko) * 2010-12-28 2011-03-07 최점미 돌침대용 온열 제어장치
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2959444T3 (es) 2013-04-04 2024-02-26 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabólicos en animales equinos
EP3082829B1 (en) 2013-12-17 2021-02-17 Boehringer Ingelheim Vetmedica GmbH Sglt2 inhibitors for the treatment of metabolic disorders in feline animals
EA032558B1 (ru) * 2014-01-23 2019-06-28 Бёрингер Ингельхайм Ветмедика Гмбх Лечение метаболических расстройств у представителей собачьих
US9624177B2 (en) * 2014-02-28 2017-04-18 Sumitomo Chemical Company, Limited Method for producing pyrazole compound
DK3721882T3 (da) 2014-04-01 2024-10-21 Boehringer Ingelheim Vetmedica Gmbh Behandling af hypofyse pars intermedia-dysfunktion hos hestedyr
KR102539788B1 (ko) 2014-09-25 2023-06-07 베링거잉겔하임베트메디카게엠베하 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료
CN105061322B (zh) * 2015-07-27 2018-07-24 北京颖泰嘉和生物科技股份有限公司 N-取代的3-羟基吡唑化合物的制备方法
MX389367B (es) 2015-08-27 2025-03-20 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2.
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
JP2025516857A (ja) 2022-05-25 2025-05-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｓｇｌｔ－２阻害薬を含む水性医薬組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1213296B1 (en) 1999-08-31 2004-04-14 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
WO2002036602A1 (en) 2000-11-02 2002-05-10 Ajinomoto Co., Inc. Novel pyrazole derivatives and diabetes remedies containing the same
SK287786B6 (sk) 2000-12-28 2011-09-05 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
EP1364957B1 (en) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
US20030054453A1 (en) 2001-04-10 2003-03-20 Millennium Pharmaceuticals, Inc. 68723, sodium/glucose cotransporter family members and uses therefor
EP1389621A4 (en) 2001-04-27 2005-05-11 Ajinomoto Kk N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
CA2448741C (en) 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
CA2484306A1 (en) 2002-04-26 2003-11-06 Katsumi Maezono Prophylactic and therapeutic agent of diabetes mellitus
US7956041B2 (en) 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
ITBO20020050U1 (it) 2002-05-13 2003-11-13 Netpack S R L Contenitore per prodotti ortofrutticoli
BRPI0313290B1 (pt) 2002-08-08 2016-12-06 Kissei Pharmaceutical derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
WO2004019958A1 (ja) 2002-08-27 2004-03-11 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
AU2003272903A1 (en) 2002-10-04 2004-04-23 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
EP1568380A4 (en) 2002-12-04 2009-10-21 Kissei Pharmaceutical PREVENTION OR TREATMENT OF DISEASES DUE TO HYPERGLYCEMIA
CN1761676A (zh) * 2003-04-01 2006-04-19 大正制药株式会社 杂芳基5－硫代－β－D－吡喃葡糖苷衍生物及含有该衍生物的糖尿病治疗药
WO2004089966A1 (ja) 2003-04-01 2004-10-21 Taisho Pharmaceutical Co., Ltd. 選択的なヘテロアリール ５－チオ－β－Ｄ－アルドヘキソピラノシドの製造法
WO2004113359A1 (ja) 2003-06-20 2004-12-29 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
CA2539032A1 (en) 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
US7375090B2 (en) * 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
JP4888840B2 (ja) 2005-07-22 2012-02-29 味の素株式会社 ピラゾール−ｏ−グリコシド誘導体の調製方法及び前記方法の新規中間体
UY29694A1 (es) 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US20080020987A1 (en) 2006-07-20 2008-01-24 Waldemar Pfrengle Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes

Also Published As

Publication number Publication date
EP1976859A1 (en) 2008-10-08
TW200745149A (en) 2007-12-16
CA2635203A1 (en) 2007-07-19
KR20090012205A (ko) 2009-02-02
EA200801663A1 (ru) 2009-02-27
JP4936234B2 (ja) 2012-05-23
UY30082A1 (es) 2007-08-31
IL192655A0 (en) 2009-02-11
US7838500B2 (en) 2010-11-23
AR058962A1 (es) 2008-03-05
PE20071237A1 (es) 2008-01-15
NO20082395L (no) 2008-07-31
NZ570311A (en) 2010-05-28
JP2009522340A (ja) 2009-06-11
US20070244176A1 (en) 2007-10-18
WO2007080170A1 (en) 2007-07-19
CN101370816A (zh) 2009-02-18
ZA200804151B (en) 2009-10-28
US20090181905A1 (en) 2009-07-16
BRPI0706375A2 (pt) 2011-03-22
US7524822B2 (en) 2009-04-28
AU2007204368A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
UY30082A1 (es) Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
AU2010202828A1 (en) System to generate related search queries
EP1958592A4 (en) intraocular lens
AR059194A1 (es) Formas de dosificacion resistentes a la manipulacion
ES1062584Y (es) Cortadora manual de ceramica
DK2049500T3 (da) Cyclopenta [d]-pyrimidiner som AKT-proteinkinase-inhibitorer
BRPI0819014A2 (pt) "descanso de braço"
BRPI0716971A2 (pt) Uso de 2-6(3-amino-piperini-l-il)-3-metil-2,4-dioxo-3,4-dihidro-2 h-pirimidin-1ilmetil-4-fluoro-benxonitrila
BRPI0823082A2 (pt) Uso derivados de sesquiterpeno
BRPI0716193A2 (pt) Replicon derivado de potexvírus
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion
BRPI0719189A2 (pt) uso de ciclosporinas modificadas
HUE038633T2 (hu) MMP-14 specifikus hasítási szekvencia
DK1753776T3 (da) Camptotheciner, som er konjugeret i 7-stillingen til cykliske peptider, som cytostatiske midler
DK1838683T3 (da) Fremgangsmåde til fremstilling af [1,4,5]-oxadiazepinderivater
EP2043776A4 (en) PREPARATION OF MONOLITHIC ARTICLES
MA28494B1 (fr) Dérivé de pyrazole cristallin
ES1067012Y (es) Cortadora manual de ceramica
FI20050004A0 (fi) Moottorilaitteisto
ITRM20060158A1 (it) Cristallino artificiale per uso intraouculare
ITRM20060440A1 (it) Uso della nifedipina per il trattamento antirughe
DE502007004416D1 (de) Avermectinderivate
DK2084130T3 (da) Fremgangsmåde til fremstilling af 5-alkyl-7H-pyrrolo[2,3-d]pyrimidin-2-oler
DE112007000709A5 (de) Multifunktionelles Wirkstoffgemisch
FI20045472A0 (fi) Tietokantasynkronointi